Risk-adapted HLA delisting and imlifidase-enabled deceased-donor kidney transplantation in highly sensitized kidney transplant candidates: a German expert consensus report - Scorecard - MDSpire

Risk-adapted HLA delisting and imlifidase-enabled deceased-donor kidney transplantation in highly sensitized kidney transplant candidates: a German expert consensus report

  • By

  • Stefan Reuter

  • Louise Benning

  • Andrea Dick

  • Lisa-Marie Dilz

  • Gunilla Einecke

  • Florian Emmerich

  • Florian Grahammer

  • Rebecca Großmann

  • Wilfried Gwinner

  • Fabian Halleck

  • Michael Hallensleben

  • Falko M. Heinemann

  • Bernd Jänigen

  • Dennis Kannenkeril

  • Teresa Kauke

  • Reinhard Kelsch

  • Stephan Kemmner

  • Malte Andreas Kluger

  • Jan Kowald

  • Andreas Kribben

  • Claudia Lehmann

  • Monika Lindemann

  • Giancarlo Maccagno

  • Christian Morath

  • Anja Mühlfeld

  • Lien Pham

  • Lutz Renders

  • Stefan Schaub

  • Sabine Scherer

  • Christian Seidl

  • Bernd Spriewald

  • Dirk Stippel

  • Julian Stumpf

  • Thuong Hien Tran

  • Rolf Weimer

  • Benjamin Wilde

  • Daniel Zecher

  • Malte Ziemann

  • Svitlana Ziganshyna

  • Nils Lachmann

  • Klemens Budde

  • June 9, 2026

  • 0 min

Share

Clinical Scorecard: HLA Delisting Based on Risk and Imlifidase-Enhanced Kidney Transplantation from Deceased Donors for Highly Sensitized Recipients: Consensus Guidelines from German Experts

At a Glance

CategoryDetail
Condition
Key MechanismsControlled delisting of unacceptable HLA antigens and use of imlifidase for desensitization.
Target Population
Care Setting

Key Highlights

    Guideline-Based Recommendations

    Diagnosis

      Management

        Monitoring & Follow-up

          Risks

            Patient & Prescribing Data

            Highly sensitized adult kidney transplant candidates.

            Imlifidase is the first approved therapy for desensitization in this population.

            Clinical Best Practices

              Related Resources & Content

              Original Source(s)

              Risk-adapted HLA delisting and imlifidase-enabled deceased-donor kidney transplantation in highly sensitized kidney transplant candidates: a German expert consensus report

              • by Stefan Reuter, Louise Benning, Andrea Dick, Lisa-Marie Dilz, Gunilla Einecke, Florian Emmerich, Florian Grahammer, Rebecca Großmann, Wilfried Gwinner, Fabian Halleck, Michael Hallensleben, Falko M. Heinemann, Bernd Jänigen, Dennis Kannenkeril, Teresa Kauke, Reinhard Kelsch, Stephan Kemmner, Malte Andreas Kluger, Jan Kowald, Andreas Kribben, Claudia Lehmann, Monika Lindemann, Giancarlo Maccagno, Christian Morath, Anja Mühlfeld, Lien Pham, Lutz Renders, Stefan Schaub, Sabine Scherer, Christian Seidl, Bernd Spriewald, Dirk Stippel, Julian Stumpf, Thuong Hien Tran, Rolf Weimer, Benjamin Wilde, Daniel Zecher, Malte Ziemann, Svitlana Ziganshyna, Nils Lachmann, Klemens Budde

              • June 9, 2026

              Related Content

              Hafnia alvei infection complicated by chorioamnionitis and septicemia: a case report and review of literature

              The stand-alone Ayurveda treatment for the management of COVID-associated mucormycosis (CAM): a case report

              MRI markers of glymphatic dysfunction in tuberculous meningitis: associations with CSF proteins and cognitive impairment